Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004158 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004158: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT00004158 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004158, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy using holmium Ho 166 DOTMP plus melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.
Interventions
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- RADIATION holmium Ho 166 DOTMP
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
What the finished NCT00004158 record still lists
NCT00004158 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00004158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004158 about?
NCT00004158 is a clinical study titled "Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy ...
What is the current status of trial NCT00004158?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00004158?
The interventions under investigation include: melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), holmium Ho 166 DOTMP (RADIATION).
Who is sponsoring clinical trial NCT00004158?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia